Skip to NavigationSkip to content

100% of multiple myeloma patients respond to Janssen's investigational CAR T therapy, data shows

Published on 14/05/20 at 01:03pm

Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, known as JNJ-4528, in the treatment of relapsed or refractory multiple myeloma

The company reported that the findings revealed a 100% response rate among participants to the therapy, and this breaks down into 97% achieving a “very good partial response or better” and 3% achieving a partial response. Evaluated participants had previously received a median of five treatment regimens, with 86% of them triple-refractory while 28% were penta-refractory.

The data further showed that, median time to response was one month, and after a median follow-up of 11.5 months, 86% of patients receiving the therapy achieved stringent complete response, while 86% of patients were alive and free of disease progression at nine months.

However, it was also noted that 100% of patients experienced the adverse event neutropenia, while 93% experienced cytokine release syndrome.

“These recently updated data from the CARTITUDE-1 study suggest a durable response and tolerable safety profile for JNJ-4528,” commented Dr Sen Zhuang, Vice President, Oncology Clinical Development at Janssen. “We continue to advance the investigation of this novel CAR-T treatment with the goal of bringing a differentiated immunotherapy to patients with multiple myeloma, many of whom have exhausted all potential prior treatment options.”

The promising findings are to be followed by longer-term follow-up data from the Phase1b portion of the study, which is due to be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program, Janssen confirmed.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches